Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
Wednesday, April 25, 2018 1 min read
Key Takeaway: Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
Full Press Release Details
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody.